Form 4: PMV Pharmaceuticals Director Carol Gallagher Reports Stock Option Grant
SEC Form 4 Filing
Director Carol Gallagher reported the acquisition and subsequent gifting of stock options in PMV Pharmaceuticals.
Summary
- Carol Gallagher, a director of PMV Pharmaceuticals, reported transactions involving stock options.
- On June 6, 2024, Gallagher acquired 67,500 stock options with an exercise price of $1.65.
- The options vest over time, with 22,500 shares vesting on the earlier of June 6, 2025, or the day prior to the next annual meeting, and the remaining 45,000 shares vesting in 36 equal monthly installments starting July 6, 2024.
- On June 7, 2024, Gallagher gifted 67,500 stock options.
- Gallagher also holds 67,500 stock options indirectly through The Gallagher Revocable Trust.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral.
Industry Context
Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with those of shareholders.
Stakeholder Impact
- The stock option grant could incentivize the director to work towards increasing shareholder value.
Key Dates
| Date | Description |
|---|---|
| January 5, 2024 | Power of Attorney executed by Carol Gallagher. |
| May 10, 2011 | Date of The Gallagher Revocable Trust. |
| June 6, 2024 | Grant date of 67,500 stock options. |
| June 7, 2024 | Gift of 67,500 stock options. |
| July 6, 2024 | Start date for monthly vesting of remaining stock options. |
| June 5, 2034 | Expiration date of the stock options. |
| June 6, 2025 | Date of first vesting tranche of stock options. |
| June 10, 2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.